NTRA Stock Risk & Deep Value Analysis
Natera Inc
DVR Score
out of 10
What You Need to Know About NTRA Stock
We analyzed Natera Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NTRA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
NTRA Risk Analysis & Red Flags
What Could Go Wrong
Natera's largest risk is failing to achieve sustained profitability despite strong revenue growth, leading to continued cash burn and dilutive capital raises. With current net losses of ~$85M per quarter, failure to control operating expenses or secure broad reimbursement for new tests could deplete its $1.1B cash reserves faster than anticipated, forcing equity financing at unfavorable terms.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Insider Selling: 219 sales and 0 purchases in the last 6 months signals a lack of conviction from company leadership regarding current valuation or future prospects.
- ⚠
Persistent Net Losses: Despite significant revenue growth and improving gross margins, Natera continues to report substantial net losses (Q1 2026: -$85.1 million), indicating challenges in controlling operating expenses.
- ⚠
High Valuation for Unprofitable Company: Current market cap of $28.08B with negative P/E suggests significant future growth is already priced in, leaving little room for error if profitability doesn't materialize quickly.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (August 6, 2026): Failure to meet -$0.60 EPS consensus or lowering of 2026 guidance, especially if oncology volume growth decelerates below 40% YoY.
- 📅
New competitor launch in cfDNA MRD (Q4 2026): A major competitor (e.g., Guardant Health, Exact Sciences) receives FDA approval for a highly effective and cost-competitive MRD test, challenging Natera’s market position.
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 25% YoY for two consecutive quarters, indicating market saturation or competitive pressure.
- 🚪
Sell if gross margin falls below 60% in any given quarter, signaling pricing pressure or increased cost of goods sold.
- 🚪
Exit if operating cash flow turns consistently negative again after Q1 2026's positive inflow, implying a worsening cash burn situation.
Unlock NTRA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Natera expands Signatera CDx into 2-3 additional high-prevalence cancer types and secures broad reimbursement by late FY2027, then its oncology revenue could reach an annualized run-rate of $1.5B-$2.0B by FY2028, leading to sustained profitability and a market capitalization of $100B+ based on its projected market leadership in the multi-billion-dollar MRD market. This is bullish because the market currently undervalues the long-term potential of Signatera and the scalability of Natera's platform to achieve significant market share and profitability once regulatory and reimbursement hurdles are cleared.
Is NTRA Stock Undervalued?
Unlock the full AI analysis for NTRA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
NTRA Price Targets & Strategy
12-Month Target
$275.00
Bull Case
$350.00
Bear Case
$170.00
Valuation Basis
Based on 8x FY2026 revenue guidance midpoint of $2.78B ($22.24B) + 12.5x growth in oncology segment revenue by mid-2027, given high growth and early-stage profitability.
Entry Strategy
Consider dollar-cost averaging on dips towards $180-$190, testing recent support levels. Aggressive investors could initiate a starter position near current levels given strong momentum.
Exit Strategy
Take 50% profit at $300, re-evaluate remaining position at $350+. Stop loss if price closes below $170 for three consecutive days.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is NTRA Financially Healthy?
Valuation
P/E Ratio
-117.31
Forward P/E
-117.31
EV/EBITDA
129.49
Price/Book
22.91
Price/Sales
13.65
Profitability
Gross Margin
65.07%
Operating Margin
-12.97%
Net Margin
-9.05%
Return on Equity
-15.13%
Revenue Growth
36.59%
EPS
$-1.64
Balance Sheet
Current Ratio
3.39
Quick Ratio
3.11
Debt/Equity
0.05
Total Debt
$198.73M
Cash & Equivalents
$1.04B
Cash Flow
Operating Cash Flow
$194.30M
Free Cash Flow
$106.07M
EBITDA
$217.30M
Other
Beta (Volatility)
1.56
Does NTRA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Natera's moat is expanding due to continuous investment in R&D, leading to new test development and regulatory approvals like Signatera CDx. The clinical validation and reimbursement pathways established are difficult for competitors to replicate quickly, offering durability for at least 10-15 years, particularly in the rapidly evolving oncology diagnostics space.
Moat Erosion Risks
- •Rapid Technological Advancements: Competitors developing superior, cheaper, or faster cfDNA sequencing technologies could erode Natera's IP advantage.
- •Reimbursement Challenges: Changes in insurance coverage policies or pricing pressure from CMS could significantly impact revenue and profitability for existing or new tests.
NTRA Competitive Moat Analysis
Sign up to see competitive advantages
NTRA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, with retail investors attracted to the long-term growth story in genomics but wary of current losses and valuation.
Institutional Sentiment
Positive, indicated by 8 Buy ratings and 0 Sell ratings, with a recent Outperform upgrade from William Blair (04/14/2026) and a median price target of $260.00, suggesting confidence in the company's growth trajectory.
Insider Activity (Form 4)
High volume of insider sales (219 transactions) and no purchases in the last 6 months, suggesting executives are taking profits or lack strong conviction at current prices.
Options Flow
Normal options activity; no specific verified unusual flow data in supplied sources.
Earnings Intelligence
Next Earnings
2026-08-06
Surprise Probability
Medium
Historical Earnings Pattern
Natera has a history of beating revenue estimates but often missing on EPS, sometimes leading to volatility. Strong revenue guidance tends to be a more significant positive driver than EPS beats.
Key Metrics to Watch
Competitive Position
Top Competitor
EXAS (Exact Sciences)
Market Share Trend
Gaining ground, particularly in the oncology MRD segment, evidenced by 54.4% YoY oncology volume growth and strategic FDA approvals like Signatera CDx in MIBC.
Valuation vs Peers
Trading at a premium on P/S due to higher growth rates in emerging segments like MRD, but also a higher discount due to current unprofitability compared to more established diagnostics peers.
Competitive Advantages
- •Proprietary Technology & IP in cell-free DNA and NGS applications for diagnostics.
- •Strong Clinical Validation & Regulatory Approvals (e.g., FDA Signatera CDx), enhancing physician trust and reimbursement prospects.
- •Broad Product Portfolio across women's health, organ health, and a rapidly expanding oncology franchise, diversifying revenue streams.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive NTRA Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (August 6, 2026): Beat consensus EPS of -$0.60 or significant positive revision to 2026 guidance, particularly if oncology revenue growth sustains above 50% YoY.
- •New NIPT/oncology test reimbursement decisions (Q3 2026): Positive coverage from a major private payer for Signatera or another key test could unlock significant market access, adding ~$50M-$100M to annual revenue run-rate.
Medium-Term (6-18 months)
- •FDA approval for Signatera in additional cancer indications (e.4 2027): Expansion into higher prevalence cancer types (e.g., CRC, lung cancer) could double the serviceable market for MRD testing, driving clinical oncology volume above 500,000 tests annually.
- •Major partnership with a pharmaceutical company for CDx development (mid-2027): A collaboration with a top-tier pharma for Signatera as a companion diagnostic with a blockbuster therapy could generate $100M-$200M in licensing/royalty revenue annually.
Long-Term (18+ months)
- •Achieving sustained free cash flow positivity by end of FY2028: If Natera transitions to generating >$200M in annual FCF, it would validate its scalable model and significantly de-risk the investment, supporting a P/FCF multiple re-rating.
- •Establishing dominant market share (>50%) in oncology MRD by FY2029: With projected oncology market opportunity in the tens of billions, achieving leadership would position Natera for a multi-hundred-billion-dollar valuation.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for NTRA?
- ✓
Watch quarterly clinical oncology test volume growth: Sustained >45% YoY growth indicates continued market penetration and thesis validation.
- ✓
Monitor gross margin trajectory: Continued improvement towards 70%+ signals better operational efficiency and pricing power.
- ✓
Track operating cash flow: Consistent positive operating cash flow for 3+ consecutive quarters would de-risk the financial health aspect significantly.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Natera Inc Makes Money
Natera is a diagnostic company specializing in cell-free DNA (cfDNA) technology, which involves analyzing DNA fragments found in blood. They primarily develop and commercialize non-invasive prenatal testing (NIPT) for pregnant women, molecular residual disease (MRD) testing (Signatera) for cancer patients to detect recurrence, and organ transplant rejection monitoring tests. Their business model involves selling these diagnostic tests directly to healthcare providers, hospitals, and increasingly, partnering with pharmaceutical companies for companion diagnostics, generating revenue through test volumes and associated reimbursement.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Natera Inc (NTRA)?
As of May 20, 2026, Natera Inc has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Natera Inc?
Natera Inc's market capitalization is approximately $28.2B..
What is the risk level for NTRA stock?
Our analysis rates Natera Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of NTRA?
Natera Inc currently has a price-to-earnings (P/E) ratio of -117.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Natera Inc's revenue growing?
Natera Inc has reported revenue growth of 36.6%. The company is showing strong top-line momentum.
Is NTRA stock profitable?
Natera Inc has a profit margin of -9.1%. The company is currently unprofitable.
How often is the NTRA DVR analysis updated?
Our AI-powered analysis of Natera Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NTRA (Natera Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.